wAIHA | Sovleplenib Demonstrates Positive Phase III Clinical Results
Recent clinical data announced by HUTCHMED indicate that sovleplenib, a novel spleen tyrosine kinase (Syk) inhibitor, has achieved positive topline results in the Phase III portion of the ESLIM-02 trial for warm antibody autoimmune haemolytic anemia (wAIHA), a rare autoimmune condition predominantly affecting adults.
wAIHA is a rare autoimmune disorder in which the immune system produces antibodies that mistakenly target and destroy red blood cells, leading to anemia and significant clinical burden.
The ESLIM-02 study is a randomized, double-blind, placebo-controlled Phase II/III trial conducted in China, enrolling adult patients with primary or secondary wAIHA who had relapsed or were refractory to at least one standard therapy. In this study, sovleplenib, an investigational oral spleen tyrosine kinase (Syk) inhibitor, met its primary endpoint, achieving a durable hemoglobin (Hb) response between weeks 5 and 24 of treatment.
Earlier results from the Phase II portion, published in The Lancet Haematology, showed encouraging hemoglobin benefits compared with placebo, with overall response rates significantly higher in the sovleplenib arm and a favorable safety profile. This reinforces the clinical potential of sovleplenib in addressing the unmet needs of patients with wAIHA.
According to the study’s principal investigators, wAIHA remains a heterogeneous and often chronic disease that can cause severe fatigue and reduced quality of life. Positive topline results from ESLIM-02 underscore the potential of sovleplenib to offer rapid and sustained hemoglobin responses, particularly for patients who have limited treatment options after standard therapies fail.
HUTCHMED plans to submit a New Drug Application (NDA) for sovleplenib for wAIHA to the China National Medical Products Administration (NMPA) in the first half of 2026, with full results from ESLIM-02 to be presented at an upcoming scientific meeting.
These findings represent a meaningful step forward in the development of targeted therapies for rare autoimmune haematological disorders and highlight the importance of continued research and collaboration to expand effective treatment options for patients worldwide.
Source: GlobeNewswire
